Artiva Biotherapeutics (NASDAQ:ARTV) Earns Buy Rating from Analysts at TD Cowen

TD Cowen began coverage on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a research note released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating on the stock.

A number of other brokerages have also commented on ARTV. Needham & Company LLC assumed coverage on shares of Artiva Biotherapeutics in a report on Tuesday. They issued a buy rating and a $23.00 price target on the stock. Wedbush started coverage on Artiva Biotherapeutics in a research note on Tuesday. They issued an outperform rating and a $18.00 target price for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and an average price target of $21.25.

Artiva Biotherapeutics Trading Down 0.6 %

ARTV stock opened at $11.36 on Tuesday. Artiva Biotherapeutics has a 1-year low of $10.50 and a 1-year high of $16.00.

Insiders Place Their Bets

In related news, Director Yong-Jun Huh acquired 2,083,332 shares of the stock in a transaction on Monday, July 22nd. The stock was purchased at an average price of $12.00 per share, for a total transaction of $24,999,984.00. Following the completion of the transaction, the director now owns 3,306,900 shares of the company’s stock, valued at approximately $39,682,800. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, major shareholder Global Strategic Fund I. Venbio bought 416,666 shares of the company’s stock in a transaction dated Monday, July 22nd. The stock was bought at an average cost of $12.00 per share, for a total transaction of $4,999,992.00. Following the completion of the acquisition, the insider now owns 1,936,637 shares in the company, valued at approximately $23,239,644. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Yong-Jun Huh purchased 2,083,332 shares of the company’s stock in a transaction that occurred on Monday, July 22nd. The stock was acquired at an average cost of $12.00 per share, with a total value of $24,999,984.00. Following the purchase, the director now directly owns 3,306,900 shares of the company’s stock, valued at $39,682,800. The disclosure for this purchase can be found here.

About Artiva Biotherapeutics

Artiva Biotherapeutics Inc is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company’s lead program includes AlloNK(R). Artiva Biotherapeutics Inc is based in SAN DIEGO.